Jeil will exclusively supply Norvatis’ 9 ophthalmic drugs
By Nho, Byung Chul | translator Alice Kang
23.12.11 08:41:23
가나다라
0
Company expects boost in sales following venture into the ophthalmology field
Set to stably supply the globally verified drugs from January
Jeil is venturing into the field of ophthalmic diseases for the first time.
Jeil Pharmaceutical (CEO Sung Suk-Je) announced on the 11th that it has signed an exclusive distribution agreement with Novartis Korea (CEO Yoo Byung-Jae) for the sale and supply of nine drugs in ophthalmic diseases including glaucoma and conjunctivitis. to target the ophthalmic disease market.
With this partnership, Jeil will be venturing into the field of ophthalmic diseases for the first time.
Jeil plans to enter the market in Jan 2024 and establish its position in the field of ophthalmic diseases, including in glaucoma and conjunctivitis.
Under the agreement, Jeil will re
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)